Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Income (Loss) per Common Share

Income (Loss) per Common Share

3 Months Ended

Feb. 28, 2017

Note 7 – Income (Loss) per Common Share

Net income (loss) per common share data are based on net income. The following table sets forth the calculation of basic and diluted (loss) earnings per share:


	For the three months ended February 28, 2017		For the three months ended February 29, 2016
Numerator:
Net Income (Loss)	$	486,923	($	122,936	)
Denominator:
Weighted-average shares outstanding-basic		6,901,108		8,971,373
Dilutive common shares issuable upon exercise of stock options		536,135		—
Weighted-average shares-diluted		7,437,243		8,971,373

Earnings (Loss) per share:
Basic	$	0.07	($	0.01	)

Diluted	$	0.07	($	0.01	)

For the three months ended February 28, 2017, the Company included the effect of all outstanding stock options in the computation of diluted earnings per share, as all of the outstanding stock options were in the money as of February 28, 2017. For the three months ended February 29, 2016, the Company excluded the effect of all outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.